

# Tuberculosis

By

**Dr. Walid Ibrahim**

**Assistant Prof. of Chest  
Diseases**


MARCH 24  
**WORLD  
TUBERCULOSIS  
DAY**



# History

- TB has been known as King's Evil, Pott's disease, consumption, and the White Plague.
- **Egyptian mummies** from 3500 BC have the presence of *Mycobacterium tuberculosis*
- It was isolated by **Robert Koch** in 1882





# **Epidemiology and Burden of Disease**

# THE TRUTH ABOUT TB

*Coughing up disturbing facts on  
World Tuberculosis Day*

It is:  
**1 of top 10**  
causes of death  
worldwide



7 countries account for **64% of TB deaths**

- India
- Indonesia
- China
- Philippines
- Pakistan
- Nigeria
- South Africa



It accounts for:

**1.7 million**  
deaths worldwide

(95% of all TB deaths  
occur in low and  
middle-income countries)

**2.5 lakh**  
child fatalities  
worldwide



**40%**  
of HIV-positive  
deaths


All figs for 2016; Source: WHO

# Burden of Tuberculosis

- **Annually** 8 million new cases  
1.7 million deaths
- 95 % from **developing countries**
- The prevalence of **multidrug-resistant TB** (MDR -TB), is increasing

# General Considerations

- ◆ Tuberculosis is a **chronic granulomatous** infection, potentially of lifelong duration, caused by *M. Tuberculosis*.
- ◆ The disease is **confined to the lungs** in most patients but may spread to any part of the body



# Aetiology


Caused by **rod shaped bacteria**

- *Mycobacterium tuberculosis*
- *Mycobacterium bovis*

**Slow growing organism**

**Strictly aerobe.**

**Susceptible to sunlight, heat  
and dryness.**






# Aetiology

## TB Bacillus is

- **Thin,**
- Length **1-5 Microns,**
- Somewhat **Curved,**
- Complex Cell Wall (Much Lipid Content) Responsible For Its Characteristic Coloration On Staining (**Acid And alcohol-fast**).



# Mycobacteria unique cell wall structure




## MYCOBACTERIUM TUBERCULOSIS (TB)


### WAXY CELL WALL

- ↳ from MYCOLIC ACID
- ↳ "ACID-FAST"

### ZIEHL-NEELEN STAIN




BRIGHT RED



ROD-SHAPED

NEEDS OXYGEN  
STRICT AEROBES

# Mycobacteria unique cell wall structure



# **Transmission Of Infection**


The background is a dark blue gradient. A thin, light blue curved line starts from the top left and arcs across the top. On the right side, there is a larger, lighter blue shape that resembles a stylized arrow or a corner element pointing towards the center.

# Modes of transmission

- 1- **Air-borne** infection:  
TB bacilli is 1-5  $\mu\text{m}$  in length  
remain in the air for long times.
- 2- Ingestion of **raw milk** & **diary**  
**products**.
- 3- **Direct invasion** through wounds




- **TB** is spread from person to person through the air via droplet nuclei
- **M. tuberculosis** may be expelled when an infectious person:
  - Coughs
  - Sneezes
  - Speaks
  - Sings
- **Transmission** occurs when another person inhales the organisms repeatedly they will become infected with tuberculosis.
- **TB** is spread easily in closed spaces over a long period of time.



## REQUIRES

- ✘ Standard Precautions
- ✘ Private room
- ✘ Door must remain closed
- ✘ Air must be filtered
- ✘ Mask
  
- ✘ If transporting pt, Pt must wear mask.



# AIRBORNE PRECAUTIONS

# The transmission is determined by

- The degree of **infectiousness of case** .
  - **Untreated positive AFB smear** cases are the most infectious
  - Patient with **cavitary lesion** is more infective
- The **intimacy and duration** of that contact



# High Risk Patients

1. Extremes of age.
2. Low immunity.
3. Contacts with open TB.
4. Over crowded populations.
5. Health workers.

*Incubation period: 4-12 weeks.*

# Pathogenesis

**Tubercle  
Bacilli**

The diagram illustrates the pathogenesis of tuberculosis. At the top, a red oval contains the text 'Tubercle Bacilli'. Below it, two cyan arrows point in opposite directions: one pointing up and one pointing down. At the bottom, another red oval contains the text 'Human Immunity'. This visualizes the reciprocal relationship between the pathogen and the host's immune system.


**Human  
Immunity**

# Human Immunity after TB

- After infection or given BCG vaccine, human will obtain **specific immunity** (*cell-mediated immunity*)
- The cellular immunity develops **within 4 - 8 weeks** after infection with TB bacilli.


# Human Immunity after TB

- **Many immunologic cells** involve in the formation of pulmonary tuberculosis.
- **Two types of cells are essential in the formation of TB**
  - ❑ **Macrophages:** directly phagocytes TB and presenting antigens to T lymphocyte
  - ❑ **T lymphocytes(CD4+):** induce protection through the production of lymphokines
  - ❑ **Langhan's giant cells**






**Special immune cells form a barrier shell** (in this example, bacilli are in the lungs)



**Shell breaks down and tubercle bacilli escape and multiply**

# Caseating Granuloma







Normal lungs



Primary infection with Ghon focus

2-8 weeks



Post-primary immunity

Incomplete immunity



Healing and calcification  
(Latent infection)



Active disease with lung  
collapse/consolidation/effusion  
and +/- miliary or extrapulmonary  
involvement

Years



Reactivation due to  
weakening of immune  
system





**Fate  
of  
pulmonary TB**

# I. *Primary pulmonary TB:*

## 1. Regression: 95%

- Healing by fibrosis and calcification
- **Ghons complex** after healing with fibrosis may undergo calcification which could be detected radiologically and called **Rank complex**

## 2. Progression

- **Pulmonary:** e.g. tuberculous pneumonia, lobar collapse (bronchial compression) or pleural effusion.
- **Extrapulmonary:**
- **Disseminated disease** e.g. lymphadenopathy (usually cervical), meningitis, pericarditis, or miliary disease

## II. Post-primary TB/ Secondary TB

- Post-primary TB is the pattern of disease that occurs in a **previously sensitized host**. It occurs after a **latent period** of months or years after primary infection.
- It may occur either by:
  - ❑ **Reactivation** of latent bacilli in response to a trigger such as weakening of the immune system by HIV infection.
  - ❑ **Reinfection**.

# Toolbox for Diagnosis of TB




# Clinical Manifestations

- *Systemic symptoms:*
  - Fever, Night sweats
  - Anorexia, Weight loss,
  - Fatigue.
- *Respiratory symptoms:*
  - **Cough** may vary from mild to severe, and **sputum** may be scant and mucoid or copious and purulent
  - **Hemoptysis** may be due to cough of a caseous lesion or bronchial ulceration
  - Chest pain

# TUBERCULOSIS (TB)

- Progressive Fatigue
- Malaise
- Anorexia
- Wt. Loss



- Chronic Cough (Productive)

- Pleuritic Chest Pain

- Night Sweats
- Hemoptysis (Advanced State)

- Low Grade Fever

## Treatment:

TB Medications for 6 Mos or Longer  
Decreased Activity  
Resp Isolation Until Negative Sputum  
Frequently Outpatient Treatment

## Diagnosis:

TB Skin Test (screening)  
Chest X-Ray  
Sputum Studies  
(3 specimens collected on different days)

# Radiology of TB


- Chest radiography is the **most important** method to detect TB.
- Tuberculosis is a great mimic
- **TB characteristics** of a chest radiograph favor the diagnosis of tuberculosis as following :



# Radiology of TB

1. Pulmonary infiltration mainly in **the upper zone**  
**Patchy, Nodular, or Cavitations** shadows
2. Presence of **calcification**.
3. **Persistence** of the abnormal shadows after non specific treatment with antibiotics.


# Primary complex




# Milliary Tuberculosis



# Post-primary pulmonary tuberculosis




Infiltrate



**Tuberculoma**

# Chronic fibro-cavitary pulmonary tuberculosis



Cavity








Figure 1. Chest X-ray showing a large, well-defined, rounded opacity in the right lung field, consistent with a pulmonary nodule or mass. The opacity is located in the lower lung zone, approximately at the level of the T10-T11 vertebral level. The rest of the lung fields appear relatively clear, and the mediastinal structures are within normal limits.














# Laboratory examinations

- Specimen examination
- Tuberculin testing

## *Types of specimens:*

- Sputum.
- BAL.
- Pleural effusions
- Blood in case of haematogenous  
TB

## 1- Sputum smears stained by Z-N stain


Three morning successive sputum samples are needed to diagnosis pulmonary TB.

Advantage: - Cheap – Rapid  
- Easy to perform  
- Specificity of 98%

### Disadvantages:

- Sputum has **low sensitivity** ( need to contain 5000-10 000 AFB/ ml.) as in **non cavitory** disease or **low bacillary** load in sputum (e.g. HIV positive patients)
- **Young children & HIV infected persons** may not produce sputum containing AFB.





## 2- Cultures on LJ media

Lowenstein –Jensen medium is an egg based media

### Advantages:

- **Specificity** about 99 %
- **More sensitive** (need lower no. of bacilli 10-100 / ml)
- **Can differentiate** between TB complex & Non-tuberculous mycobacterium (NTM) using biochemical reactions
- **Susceptibility tests** for antituberculous drugs ( St, INH, Rif., E)

Disadvantages: Slowly growing ( up to **8 weeks**)

**CONTROL**



**NEGATIVE**



**POSITIVE**



*Mycobacterium tuberculosis* growing on Lowenstein-Jensen (LJ) Medium

# Recent Methods for Diagnosis

## II-BACTEC 460 ( rapid radiometric culture system)

- ❑ Specimens are cultured in a liquid medium (Middlebrook 7H9 broth base ).
- ❑ Growing mycobacteria utilize the acid, releasing radioactive CO<sub>2</sub> which is measured as growth index (GI) in the BACTEC instrument.

## Advantages :

- **Rapid** (mycobacteria can be detected within 12 days.)
- Determining **drug susceptibility** .
- Differentiating between **TB complex & NTM** by NAP test.
- **Specificity** is very high

## Disadvantages:

- **Expensive**
- Hazards of using **radioactive material**.

# INVESTIGATIONS


- **BACTEC media:** for faster culture (within 1-2wks)



Bactec 460



Bactec9000MB



Bactec mgit960b

## II-Polymerase Chain Reaction (PCR)

Nucleic acid probe amplification tests in which polymerase enzymes are used to amplify ( make many copies of specific DNA or RNA sequences extracted from mycobacterial cells.

### Advantages:

- Rapid procedure ( 3 – 4 hours)
- High sensitivity (1-10 bacilli / ml sputum)


### Disadvantages

- Very expensive.
- Can not differentiate between living & dead bacilli.


# Tuberculin Skin Testing

## Mantoux Test

5 TU of PPD



48 - 72  
hours







**Mantoux tuberculin skin test**

# Reading the TST

- Measure reaction in **48 to 72** hours
- Measure **induration**, not erythema
- Record reaction in **millimeters**, not “negative” or “positive”
- **Trained health care professional** measures and interprets the TST



- ❑ Tuberculin skin testing is the most common method used to screen for latent *M tuberculosis*.
- ❑ Positive tuberculin skin test indicates tuberculous infection , with or without disease

Positive  $\Rightarrow$  Infection and Immunity

# Positive Tuberculin Test

Size of induration	Considered positive in :
$\geq 5$ mm for	<ol style="list-style-type: none"><li>1. Close contacts of active pulmonary.</li><li>2. HIV-immunocompromised persons</li><li>3. Persons with fibrotic chest x-ray findings consistent with old TB.</li><li>4. Organ transplant recipients or other immunosuppressed persons (including persons receiving long-term, high dose oral or parenteral corticosteroid therapy (&gt;15 mg prednisone, or equivalent, daily for 1 month or longer)).</li></ol>


Size of induration	Considered positive in :
<p style="text-align: center;">≥ 10 mm for</p>	<p>1. Persons with certain medical conditions e.g.,</p> <ul style="list-style-type: none"> <li>○ Silicosis,</li> <li>○ Chronic renal failure,</li> <li>○ Diabetes mellitus,</li> <li>○ Some cancers, leukaemia, and lymphoma</li> <li>○ Gastrectomy/jejunioileal bypass</li> </ul> <p>2. Health care and laboratory workers.</p> <p>3. Persons who have immigrated within the past 5 years from areas with high prevalence</p> <p>4. Persons with prolonged stay (&gt;1month) in areas with high TB e.g. prisons</p> <p>5. Injection drug users.</p> <p>6. Persons over age 70 and children &lt; 4 years of age.</p>
<p style="text-align: center;">≥ 15 mm for</p>	<p>Considered positive in all peoples even in vaccinated persons</p>

- *False negatives:*
  - Anergy (immunocompromised or malnutrition)
  - Recent TB infection
  - Very young age (< 6 months)
  - Deeper injection of TST.
- *False positives:*
  - BCG vaccination
  - Nontuberculous mycobacterial infections
  - Inaccurate reading of TST
- A reaction of **less than 5 mm** is considered **negative**.

- **Latent TB Infection (LTBI):** TB infection without evidence of clinically active disease:

- Positive tuberculin test,
- No symptoms of active disease,
- CXR usually normal, or abnormal, but no evidence of active disease,
- Sputa negative for acid-fast bacilli.

- **TB Disease:** active tuberculous infection of any organ

The diagram illustrates the human respiratory system, including the trachea and bronchi. It is split into two halves to compare latent TB and active TB disease. The left lung is labeled 'Latent TB' and shows a small cluster of blue rod-shaped bacteria within a yellow circular capsule. The right lung is labeled 'TB Disease' and shows a larger, more active cluster of blue rod-shaped bacteria, with some individual bacteria scattered throughout the lung tissue.

## Latent TB

- TB lives but doesn't grow in the body
- Doesn't make a person feel sick or have symptoms
- **Can't** spread from person to person
- Can advance to TB disease

## TB Disease

- TB is active and grows in the body
- Makes a person feel sick and have symptoms
- **Can** spread from person to person
- Can cause death if not treated



# BCG and TST

- BCG is administered to more than **80% of children** in the world as part of the Extended Program of Immunization.
- **Reactivity from BCG** wanes after a few years and is unlikely to persist > 10 years,
- 
- Reactions to the TST following BCG vaccination mostly range from **5-9 mm range**.
- 
- TST reactions of **15 mm or greater** are likely to be positive







# QuantiFERON<sup>®</sup> -TB Gold, “IGRA”

---

- Whole blood assay
  - Stimulate lymphocytes with specific antigen ESAT-6 and CFP10
  - Measure IFN- $\gamma$  level by
    - Enzyme-linked immunosorbent assay
- Approved by FDA, USA in May 2005



# QuantiFERON<sup>®</sup> -TB Gold

---

## *Advantages Of QFT-G*

- **Greater specificity.**
  - No cross reactivity with previous **BCG** vaccination
  - No cross reactivity with **Non Tuberculous Mycobacteria (NTM)** .
- **Error elimination:**
  - Deeper injection in the TST produces a common error—the solution may be “washed out” by vascular flow, resulting in a possible **false-negative result**.



# QuantiFERON<sup>®</sup> -TB Gold

---

- **Faster results.:**
  - QFT-G results are available as **quickly as 24 hours** after blood collection; the TST requires 2-3 day wait as well as a **return visit by the patient**.
- **QFT-G is an in vitro test**
  - Never exposes the person to its antigenic proteins, so not **generate “Booster Phenomenon”**.



---

# Differential Diagnosis

**Pulmonary**

**Extra-Pulmonary**

# Anti TB Drugs



A circular arrangement of various colorful pills and capsules, including pink, yellow, blue, green, orange, white, black, and red pills, surrounding the word "Tuberculosis" written in red cursive script.

*Tuberculosis*

## Goals of antitubercular chemotherapy

- *Kill dividing bacilli:* Drugs with early bactericidal action rapidly reduce bacillary load in the patient and achieve quick sputum negativity so that transmission of TB is interrupted. This also affords quick symptom relief.
- *Kill persisting bacilli:* To effect cure and prevent relapse. This depends on sterilizing capacity of the drug.
- *Prevent emergence of resistance:* The relative activity of the first line drugs in achieving these goals.

# Basic Principles of Treatment

---

- Determine the **patient's HIV status**- this could save their life!
- **Multiple drugs** to which the organisms are susceptible
- **Never add single drug** to failing regimen
- **Ensure adherence** to therapy (DOT)



	FIRST LINE	Second Line
<b>C I D A L</b>	Rifampin Isoniazid Streptomycin Pyrazinamide	<b>Quinolone:</b> Levo, O, cipro-floxacin <b>Aminoglycosides:</b> <b>Amikacin, kana</b> <b>Capreomycin</b> <b>Rifamycins:</b> Rifabutin Rifapentin <b>Macrolides:</b> Clarithro, azithro <b>Linezolid</b>
<b>STATIC</b>	Ethambutol	Cycloserine, PAS, Clofazimine, Ethionamide Thiacetazone

# Treatment Recommendations

New Patients (not previously treated)

**Initial Phase**

(2 months)

INH, RIF, PZA, EMB daily

**Continuation Phase**

(4 months)

INH, RIF daily

INH, RIF 3x/wk

**Table 3a: WHO recommended doses of the first-line anti-tuberculosis drugs**

<b>Drugs</b>	<b>Daily doses (mg/kg)</b>	<b>Route</b>	<b>Thrice weekly dosage (mg/kg/dose)</b>
Isoniazid (H)	5 (4–6)	Oral	10 (8–12)
Rifampin (R)	10 (8–12)	Oral	10 (8–12)
Ethambutol (E)	15 (15–20)	Oral	30 (25–35)
Pyrazinamide (Z)	25 (25–30)	Oral	35 (30–40)
Streptomycin (S)	15 (12–18)	Oral	15 (12–18)

**Table 3b: Recommended doses of second-line anti-TB drugs**

<b>Drugs</b>	<b>Daily doses (mg/kg)</b>	<b>Route</b>	<b>Maximum daily dose</b>
Kanamycin (K)	15	IM	Up to 1 g
Amikacin (A)	15	IM	Up to 1 g
Ethionamide (Eto)	10–15	Oral	Up to 1 g
Cycloserine (Cs)	10	Oral	Up to 1 g
Para amino salicylic acid (PAS)	250	Oral	Up to 1 g
Ofloxacin (Ofx)	15–20	Oral	800–10000 mg
Levofloxacin	7.5–10	Oral	750-1000 mg
Moxifloxacin	7.5–10	Oral	400 mg

# Drug Administration


- The first-line medications should be administered together as single dose rather than in divided doses.
- A single dose leads to:
  - Higher peak serum concentrations
  - Potentially more effective,
  - Facilitates using DOT.
- Thus, if patients have Epigastric distress or nausea with the first-line drugs, dosing with food is recommended.

# 1- Isoniazid (INH) First-line drug

- Isoniazid is a **principal agent** used to treat tuberculosis & **universally accepted** for initial treatment
- It should be included in **all TB treatment regimens** unless the organism is resistant
- Structural similarity to **pyridoxine**.
- **MOA:** Isoniazid **inhibits synthesis of mycolic acids**, which are essential components of mycobacterial cell walls.



# Mycobacteria unique cell wall structure



## Adverse effects

The two most important adverse effects of isoniazid therapy are :

- **Hepatotoxicity** and
- **Peripheral neuropathy**
  - It's a **dose-dependent** 2 - 20 % and probably relates to interference with **pyridoxine metabolism**
  - This rate can be reduced with the prophylactic administration of **25 mg of pyridoxine daily**

## 2-Rifampicin (RFP) First-line drug

- It can kill dormant organisms that are poorly accessible to many other drugs, such as **intracellular** organisms and those in Acidic environment of **caseous foci**.
- **MOA: It inhibits RNA synthesis** by binding to the  $\beta$ -subunit of DNA-dependent RNA polymerase and thereby inhibits RNA synthesis.

## Adverse effects

The most important adverse effects of rifampicin therapy are :

- Hepatitis,
- Hepatic microsomal enzymes inducer,
- Gastrointestinal upset,
- Red discoloration of body fluids.

# Rifampicin drug interactions

- Microsomal enzyme inducer → ↓ plasma concentration of certain drugs → ↓ drug efficacy.
- Examples:
  - Combined-oral contraceptives
  - Warfarin
  - Corticosteroids
  - Phenytoin
  - Sulphonylurea hypoglycaemics
  - Statins
  - Theophylline
  - Methadone
  - T4

## 3-Pyrazinamide (PZA) First-line drug

- Pyrazinamide is a **major oral agent** used against mycobacteria
- The drug exert greatest activity against **dormant** organisms contained within:
  - Macrophages
  - Acidic environment of caseous foci.

## Adverse effects

The most important adverse effects of Pyrazinamide therapy are :

- **Hepatotoxicity** is a prominent side effect (1-3 %),
- **Hyperuricemia** may provoke acute gouty arthritis.
- **Gastrointestinal upset.**

## 4- Ethambutol

## First-line drug

- It is used often to protect against the emergency of drug resistance
- Bacteriostatic
- The most common serious adverse effect is dose-related optic neuritis, causing loss of visual acuity and red-green color-blindness, but are reversible.



## 5-Streptomycin (SM) First-line drug

- It is administered only parenterally, **intramuscular**
- The dosage must be lowered and the frequency of administration reduced (to only two or three times per week) in most patients **over fifty years old** and in any patient with **renal impairment**

## *Adverse effects*

- Ototoxicity
- Renal toxicity

# Adverse Drug Reactions

Drug	Adverse Reaction	Signs and Symptoms
Isoniazid	- <b>Peripheral neuropathy</b>	- Tingling sensation in hands and feet
Rifampin	- <b>Hepatitis,</b> - <b>Hepatic microsomal enzymes inducer,</b>  - <b>Gastrointestinal upset,</b> - <b>Red discoloration of body fluids.</b>	- Abnormal liver function test - ↓ effect of oral contraceptives, corticosteroids, theophylline, phenytoin, warfarin - Abdominal pain Anorexia, Nausea, Vomiting - Yellowish skin or eyes Dark urine

# Adverse Drug Reactions

Caused by	Adverse Reaction	Signs and Symptoms
Pyrazinamide	<ul style="list-style-type: none"><li>- GIT Upset</li><li>- Arthralgia</li><li>- Hyperuricemia</li></ul>	<p>Anorexia, nausea, vomiting</p> <p>Joint aches</p> <p>Gout (rare)</p>
Ethambutol	<ul style="list-style-type: none"><li>- Optic neuritis</li></ul>	<p>Blurred vision</p> <p>Changed color vision</p>
Streptomycin	<ul style="list-style-type: none"><li>- Ear damage</li><li>- Kidney damage</li></ul>	<p>Loss of hearing, Ringing in the ears</p> <p>Abnormal kidney function test</p>

# Extrapulmonary TB

---

- In most cases, treat with same regimens used for pulmonary TB

## Bone and Joint TB, Miliary TB, or TB Meningitis in Children

- Treatment extended > 6 months depending on site of disease
- In TB meningitis Streptomycin replaced by Ethambutol



# Dosing recommendations in Renal Insufficiency (CC <30ml/min) and Hemodialysis)

<b>Drug</b>	<b>Recommended dose and frequency</b>
<b>INH</b>	<b>300</b> mg once daily ,or 900 mg 3times/week (as)
<b>RIF</b>	<b>600</b> mg once daily ,or 600 mg 3times/week (as)
<b>EMB</b>	<b>15-25</b> mg/kg/dose 3times/week (not daily)
<b>PZA</b>	<b>25-35</b> mg/kg/dose 3times/week (not daily)
<b>Levofloxacin</b>	<b>750-1000</b> mg /dose 3times/week (not daily)
<b>Streptomycin</b>	<b>15</b> mg/kg/dose 2-3times/week (not daily)



# DRUG-RESISTANT TUBERCULOSIS



**1,042**

DRUG-RESISTANT  
TUBERCULOSIS CASES  
IN 2011 (U.S.)



**10,528**

TUBERCULOSIS  
CASES IN 2011  
(U.S.)

THREAT LEVEL  
**SERIOUS**



This bacteria is a serious concern and requires prompt and sustained action to ensure the problem does not grow.



TUBERCULOSIS IS AMONG THE MOST COMMON INFECTIOUS DISEASES AND  
**FREQUENT CAUSES OF DEATH WORLDWIDE**



# MDR-TB

- ❑ IT is resistant to both INH and Rifampicin.
- ❑ We can select five anti-TB drugs , these drugs include:
  - ❑ Quinolones (Levofloxacin, ofloxacin),
  - ❑ Aminoglycosides (amikacin, kanamycin, capremycin)
  - ❑ EMB,
  - ❑ PZA,
  - ❑ Cycloserine,
  - ❑ Ethionamide.
- ❑ The whole therapy lasts at least 18 months.



# Causes of MDR

## HEALTH-CARE PROVIDERS: INADEQUATE REGIMENS

Inappropriate guidelines  
Noncompliance with  
guidelines  
Absence of guidelines  
Poor training  
No monitoring of  
treatment  
Poorly organized or funded  
TB control programmes

## DRUGS: INADEQUATE SUPPLY OR QUALITY

Poor quality  
Unavailability of certain  
drugs (stock-outs or  
delivery disruptions)  
Poor storage conditions  
Wrong dose or  
combination

## PATIENTS: INADEQUATE DRUG INTAKE

Poor adherence (or poor  
DOT)  
Lack of information  
Lack of money (no treatment  
available free of charge)  
Lack of transportation  
Adverse effects  
Social barriers  
Malabsorption  
Substance dependency  
disorders

# XDR= extensively drug-resistant TB

Resistance to at least Rifampicin and isoniazid, in addition to any Fluoroquinolones, and to at least one of the three following injectable drugs used in anti-TB treatment: Capreomycin, kanamycin and Amikacin.

# Treatment Monitoring


---

- **Sputum smear microscopy** for AFB at 2 months. If positive at two months, repeat at 3 months
- If still smear positive at 3 months, continuation phase is still started while awaiting **DST results**



Did you know that ...

**TB IS CURABLE!**



**TREATMENT IS FREE**

Kanhchana



We don't have  
TB.

Hand-in-hand we can fight for a World Free of TB.



The image features the words "THANK YOU" in a bold, 3D, sans-serif font. The text is rendered in a bright blue color with a glowing, ethereal effect. A light blue beam of light originates from the right side of the text and extends towards the top right corner of the frame. The background is a dark, gradient blue, with a thin, curved white line arching across the top. The overall aesthetic is clean and modern.

THANK YOU